# Revenue from major products

The following is an analysis of the Group’s revenue from its major products:

<table><tr><td rowspan="4"></td><td colspan="3">Year ended 31 December</td><td colspan="2">Six months ended
30 June</td></tr><tr><td>2007</td><td>2008</td><td>2009</td><td>2009</td><td>2010</td></tr><tr><td>US$’000</td><td> US$’000</td><td> US$’000</td><td> US$’000</td><td>US$’000</td></tr><tr><td></td><td></td><td></td><td>(unaudited)</td><td></td></tr><tr><td>Deanxit ....................</td><td>26,144</td><td>36,710</td><td>44,468</td><td>22,768</td><td>26,029</td></tr><tr><td>Ursofalk ....................</td><td>14,756</td><td>21,074</td><td>28,327</td><td>13,393</td><td>16,937</td></tr><tr><td>Augentrofpen Stulln Mono edye-rops . .</td><td>3,011</td><td>4,394</td><td>6,146</td><td>2,817</td><td>3,814</td></tr><tr><td>GanFuLe....................</td><td>2,599</td><td>3,910</td><td>4,780</td><td>2,243</td><td>2,004</td></tr><tr><td>XinHuoSu ...................</td><td> —</td><td>2,839</td><td>7,253</td><td>2,983</td><td>5,697</td></tr><tr><td>Salofalk . . . . . . . . . . . . . . . . . . . .</td><td> —</td><td>133</td><td>1,824</td><td>658</td><td>1,684</td></tr><tr><td>Cystistat . . . . . . . . . . . . . . . . . . . .</td><td> —</td><td>66</td><td>515</td><td>171</td><td>319</td></tr><tr><td>Exacin ....................</td><td>—</td><td>—</td><td>—</td><td>—</td><td>3,367</td></tr><tr><td>Bioflor ....................</td><td>—</td><td> —</td><td> —</td><td> —</td><td>282</td></tr><tr><td>Others .....................</td><td>5,237</td><td>3,474</td><td>3,141</td><td>1,742</td><td>1,062</td></tr><tr><td>Total ......................</td><td>51,747</td><td>72,600</td><td>96,454</td><td>46,775</td><td>61,195</td></tr></table>

# 6. OTHER GAINS AND LOSSES

<table><tr><td rowspan="4"></td><td colspan="3">Year ended 31 December</td><td colspan="2"> Six months ended 30 June</td></tr><tr><td>2007</td><td>2008</td><td>2009</td><td>2009</td><td>2010</td></tr><tr><td>US$’000</td><td> US$’000</td><td> US$’000</td><td> US$’000</td><td>US$’000</td></tr><tr><td></td><td></td><td></td><td>(unaudited)</td><td></td></tr><tr><td>Service fee income . . . . . . . . . . . . . .</td><td> —</td><td>771</td><td> —</td><td> —</td><td> —</td></tr><tr><td>Net exchange gain (loss) . . . . . . . . . .</td><td>655</td><td>743</td><td>(405)</td><td>(272)</td><td>(109)</td></tr><tr><td>Government subsidies (Note) . . . . . . .</td><td>1</td><td>623</td><td>801</td><td>161</td><td>240</td></tr><tr><td>Interest income . . . . . . . . . . . . . . . .</td><td>236</td><td>221</td><td>329</td><td>94</td><td>302</td></tr><tr><td>Gain on disposal of a subsidiary . . . . .</td><td> —</td><td> —</td><td>24</td><td> —</td><td> —</td></tr><tr><td>Loss on disposal of an associate
(Note 18) . . . . . . . . . . . . . . . . .</td><td> —</td><td> —</td><td>(70)</td><td> —</td><td> —</td></tr><tr><td>Fair value change on investments held
for trading . . . . . . . . . . . . . . . . .</td><td>288</td><td>158</td><td>81</td><td>14</td><td>81</td></tr><tr><td>Imputed interest income on
available-for-sale investment . . . . . .</td><td>30</td><td>20</td><td> —</td><td> —</td><td> —</td></tr><tr><td>(Loss) gain on disposal of property,
lpant and equipment. . . . . . . . . . .</td><td>(8)</td><td>2</td><td>7</td><td>(2)</td><td>6</td></tr><tr><td>Impairment loss recognised on property,
lant and equipment (Note 14p) ....</td><td> —</td><td> —</td><td>(805)</td><td> —</td><td> —</td></tr><tr><td>Discount on acquisition of an associate
(Note 18) . . . . . . . . . . . . . . . . .</td><td> —</td><td> —</td><td>647</td><td>647</td><td> —</td></tr><tr><td>Others . . . . . . . . . . . . . . . . . . . . .</td><td>78</td><td>152</td><td>53</td><td>49</td><td>26</td></tr><tr><td></td><td>1,280</td><td>2,690</td><td>662</td><td>691</td><td>546</td></tr></table>

Note: The amount represents the incentive subsidies provided by the PRC local authorities to the Group to encourage performance of the research and development. There are no specific conditions attached to the grants, the Group recognised the grants upon receipts.

# 7. FINANCE COSTS

<table><tr><td rowspan="4"></td><td colspan="3">Year ended 31 December</td><td colspan="2"> Six months ended 30 June</td></tr><tr><td>2007</td><td>2008</td><td>2009</td><td>2009</td><td>2010</td></tr><tr><td>US$’000</td><td> US$’000</td><td> US$’000</td><td> US$’000</td><td>US$’000</td></tr><tr><td></td><td></td><td></td><td>(unaudited)</td><td></td></tr><tr><td>Interest on bank loans wholly repayable
within five years . . . . . . . . . . . . .</td><td>301</td><td> —</td><td>43</td><td> —</td><td>187</td></tr><tr><td>Imputed interest on deferred
consideration payables . . . . . . . . .</td><td> —</td><td>226</td><td>347</td><td>191</td><td>149</td></tr><tr><td></td><td>301</td><td>226</td><td>390</td><td>191</td><td>336</td></tr></table>

# 8. DIRECTORS’ AND EMPLOYEES’ EMOLUMENTS

<table><tr><td rowspan="4"></td><td colspan="3">Year ended 31 December</td><td colspan="2"> Six months ended 30 June</td></tr><tr><td>2007</td><td>2008</td><td>2009</td><td>2009</td><td>2010</td></tr><tr><td>US$’000</td><td> US$’000</td><td> US$’000</td><td> US$’000</td><td>US$’000</td></tr><tr><td></td><td></td><td></td><td>(unaudited)</td><td></td></tr><tr><td>Directors’ fees . . . . . . . . . . . . . . . .</td><td>188</td><td>193</td><td>161</td><td>77</td><td>81</td></tr><tr><td>Other emoluments to non-executive
directors and independent
non-executive directors .........</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td></tr><tr><td>Other emoluments to executive
directors</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>- basic salaries and allowances . . . .</td><td>308</td><td>328</td><td>340</td><td>173</td><td>151</td></tr><tr><td>- retirement benefits scheme
contributions . . . . . . . . . . . . .</td><td>17</td><td>12</td><td>15</td><td>4</td><td>8</td></tr><tr><td></td><td>513</td><td>533</td><td>516</td><td>254</td><td>240</td></tr></table>